| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | YL54 | CTRPv2 | pan-cancer | AAC | -0.067 | 0.1 |
| mRNA | BRD-A71883111 | CTRPv2 | pan-cancer | AAC | -0.062 | 0.1 |
| mRNA | LY317615 | GDSC1000 | pan-cancer | AAC | 0.057 | 0.1 |
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | -0.062 | 0.1 |
| mRNA | HLI 373 | CTRPv2 | pan-cancer | AAC | -0.06 | 0.1 |
| mRNA | BRD-K34222889 | CTRPv2 | pan-cancer | AAC | -0.052 | 0.1 |
| mRNA | NG-25 | GDSC1000 | pan-cancer | AAC | -0.05 | 0.1 |
| mRNA | BRD-K64610608 | CTRPv2 | pan-cancer | AAC | 0.065 | 0.1 |
| mRNA | ABT-263 | CTRPv2 | pan-cancer | AAC | -0.059 | 0.1 |
| mRNA | navitoclax:piperlongumine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.06 | 0.1 |